$4.01+0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $2.4M | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Artiva Biotherapeutics, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“After careful consideration, we have made the difficult decision to discontinue development of AlloNK and to pursue strategic alternatives,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Artiva is a clinical-stage biotechnology company that has focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases. AlloNK ® (AB-101), the Company’s lead development candidate, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy that was evaluated in combination with B-cell-targeted monoclonal antibodies. On October 27, 2026, Artiva announced the discontinuation of further clinical development of AlloNK and the initiation of an evaluation of strategic alternatives. Artiva is headquartered in San Diego, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Artiva Biotherapeutics, Inc.’s Item 2.02 8-K filed October 27, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.